

CD19 (ZM179)

Recombinant Monospecific Mouse Monoclonal Antibody

Specificity: Humans

Immunogen: A synthetic peptide from the c-terminus of human CD19 protein

Ig Class: IgG2a /k

Storage: Store at 2-8°C for up to 2 years for concentrate form and 1 year for predilute form

Staining procedures: Use formalin-fixed and paraffin-embedded sections. *Retrieval conditions:* Pretreatment of deparaffinized tissue with heat-induced epitope retrieval is recommended. *Detection methods:* Polymer anti-mouse/rabbit Ig detection system. *Working dilution:* 1:100-200. *Positive Control:* Lymph node or tonsil. *Localization:* Membrane. *Intended Use:* Research Use Only (RUO).

Description: In normal lymphoid tissue CD19 is observed in germinal centers (on both B cells and follicular dendritic cells), in mantle zone cells and in scattered cells in the interfollicular areas, with an overall immunoreactivity pattern similar to that of CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in pre-B cells. CD19 positivity is seen in the vast majority of B-cell neoplasms (B-lymphoblastic lymphoma, small lymphocytic lymphoma/CLL, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, T-cell-rich B-cell lymphoma, lymphoblastic lymphoma, hairy cell leukemia) and commonly at a lower intensity than normal B-cell elements. Plasma cell neoplasms are consistently negative as are T-cell neoplasms. CD19 was undetectable in 14% of diffuse large B-cell lymphomas, 30% of T-cell-rich B-cell lymphomas and 75% of post-transplant B-lympho-proliferative disease. CD19 expression is not seen in Reed-Sternberg cells of classic Hodgkin lymphoma.

Intended Use: This antibody is intended for research use only (RUO). CD19 (ZM179) mouse monoclonal primary antibody is intended for laboratory use in the detection of CD19 in formalin-fixed, paraffin-embedded tissue by immunohistochemical (IHC) staining. The staining results should be interpreted by qualified pathologists in conjunction with the patient's relevant clinical history.

Supplied As: Purified antibody in Tris-HCl buffer containing stabilizing protein and <0.1% sodium azide.

References:

1. Kimura M, et al. Int J Hematol. 2007; 85:41-8.
2. Masir N, et al. Histopathology. 2006; 48:23946.
3. Greenberg SA, et al. Neurology. 2005; 65:1782-7.

REF Z2481ML-R/ Z2481MS-R/ Z2481MT-R/ Z2481MP-R (1.0ml Concentrate/ 0.5ml Con./ 0.1ml Con./ 7ml Pre-dil)